Infectious bursal disease virus (IBDV) mutant expressing virus neutralising epitopes specific for classic-and variant IBDV strains
The present invention provides a classic IBDV mutant that additionally comprises virus neutralising epitopes 67 (specific for variant-E IBDV).
1. A classic infectious bursal disease virus (IBDV) mutant that expresses a VP2 protein that binds with monoclonal antibody (moab) B69, wherein the VP2 protein also binds with moab 67, secreted by hybridoma cell lines HB-9437 and HB-11122, deposited at the ATCC, Rockville, USA, respectively, wherein the mutant comprises one or more mutations in a classic VP2 coding region, such that the coding region comprises,
(i) a codon for the amino acid at position 222 encoding an amino acid selected from the group consisting of serine and threonine, and
(ii) a nucleotide sequence encoding an amino acid sequence selected from the group consisting of SEQ ID. No. 2, SEQ ID. No. 3, SEQ ID. No. 4 and SEQ ID. No. 5 at positions 318-323.
2. A classic IBDV mutant according to claim 1 , wherein the coding region comprises a codon for the amino acid at position 330 encoding an amino acid selected from the group consisting of arginine and serine.
3. The classic IBDV mutant according to claim 1 , wherein the mutant comprises one or more mutations in a VP2 coding region of IBDV strain D78.
4. The classic IBDV mutant according to claim 1 , wherein the mutant comprises a genomic segment A of IBDV strain D78.
5. An immunogenic composition for raising antibodies in poultry against IBDV comprising a classic IBDV mutant according to claim 1 , together with a pharmaceutically acceptable carrier or diluent.
6. The immunogenic composition according to claim 5 , wherein the classic IBDV mutant is in a live form.
7. The immunogenic composition according to claim 5 , which further comprises one or more of other pathogens infectious to poultry.
8. The immunogenic composition according to claim 5 , which comprises an adjuvant.
9. A classic infectious bursal disease virus (IBDV) mutant that expresses a VP2 protein that binds with monoclonal antibody (moab) B69, wherein the VP2 protein also binds with moab 67, secreted by hybridoma cell lines HB-9437 and HE-11122, deposited at the ATCC, Rockville, USA, respectively, wherein the mutant comprises one or more mutations in a classic VP2 coding region, such that the coding region comprises,
(i) a codon for the amino acid at position 222 encoding threonine, and
(ii) a nucleotide sequence encoding an amino acid sequence selected from the group consisting of SEQ ID. No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID. No. 4, and SEQ ID No. 5 at positions 318-323.
10. The classic IBDV mutant according to claim 9 , wherein the coding region comprises a codon for the amino acid at position 330 encoding an amino acid selected from the group consisting of arginine and serine.
11. The classic IBDV mutant according to claim 9 , wherein the mutant comprises one or more mutations in a VP2 coding region of IBDV strain D78.
12. The classic IBDV mutant according to claim 9 , wherein the mutant comprises a genomic segment A of IBDV strain D78.
13. An immunogenic composition for raising antibodies in poultry against IBDV comprising a classic IBDV mutant according to claim 9 , together with a pharmaceutically acceptable carrier or diluent.
14. The immunogenic composition according to claim 13 , wherein the classic IBDV mutant is in a live form.
15. The immunogenic composition according to claim 13 , which further comprises one or more immunogens of other pathogens infectious to poultry.
16. The immunogenic composition according to claim 13 , which comprises an adjuvant.